Yes, Beta Sheet Mutations Frequently Trigger Protein Misfolding in Diseases
Mutations that alter beta sheet structures—key elements of protein secondary structure—often destabilize folding pathways, promote aggregation, or shift proteins into toxic conformations. This drives diseases like Alzheimer's, Parkinson's, and amyloidosis, where misfolded proteins form beta-sheet-rich fibrils or plaques.[1][2]
How Beta Sheet Mutations Cause Misfolding
Beta sheets rely on hydrogen bonds between backbone atoms for stability. Mutations in residues forming these sheets can:
- Disrupt hydrogen bonding, weakening sheet integrity and exposing hydrophobic cores.
- Introduce steric clashes or charge imbalances, favoring aberrant folding.
- Enhance beta-strand propensity, leading to intermolecular associations and amyloid fibrils.
For instance, point mutations in beta sheets propagate misfolding via seeded aggregation, where one faulty protein templates others.[3]
Key Examples in Specific Diseases
Amyloidosis and ATTR: Mutations in transthyretin (TTR), which has beta-sheet-rich domains, replace stabilizing residues (e.g., Val30Met). This destabilizes the tetramer, exposing beta sheets for fibril formation, causing cardiac and nerve damage.[4]
Prion Diseases: In Prusiner's model, PrP^Sc adopts an expanded beta-sheet conformation from PrP^C's alpha-helical form due to mutations like Octapeptide repeat insertions. This infectious misfold spreads via templating.[5]
Huntington's Disease: Polyglutamine expansions in huntingtin's exon 1 create beta-sheet-prone hairpins, forming nuclear inclusions that impair neuronal function.[6]
Type II Diabetes: Islet amyloid polypeptide (IAPP) mutations enhance beta-sheet stacking into pancreatic amyloids, killing beta cells.[7]
Evidence from Structural Studies
Cryo-EM and NMR show disease mutants increase beta-sheet content: Alzheimer's Aβ42 plaques have cross-beta architecture, with mutations like Dutch E22Q stabilizing protofibrils.[8] Computational models confirm beta-sheet mutations lower folding energy barriers to aggregates.[9]
Differences from Alpha-Helix or Other Mutations
Unlike alpha-helix mutations, which often cause loss-of-function via unfolding, beta-sheet changes uniquely drive gain-of-toxic-function through aggregation. Beta mutations propagate prion-like, while helix ones rarely do.[2][10]
Can These Be Reversed or Treated?
Small molecules like tafamidis stabilize TTR beta sheets, preventing misfolding in ATTR.[11] Antisense oligonucleotides target mutant huntingtin. Gene editing (e.g., CRISPR) corrects prion mutations in models, but clinical use lags.[12]
Ongoing Research and Uncertainties
Debate persists on whether beta-sheet expansion is cause or consequence in some cases, like Parkinson's α-synuclein, where mutations (A53T) amplify sheets but environmental factors contribute.[13] Clinical trials test beta-sheet disruptors, with phase 3 data expected 2025 for Alzheimer's.
[1] Nature Reviews Molecular Cell Biology - Protein Misfolding Diseases
[2] Cell - Mechanisms of Amyloid Formation
[3] PNAS - Seeded Aggregation from Beta Mutations
[4] NEJM - TTR Mutations in ATTR
[5] Science - Prion Protein Structures
[6] Nature Structural Biology - Huntingtin Beta Sheets
[7] Biochemistry - IAPP Amyloids
[8] Nature - Aβ Fibril Structures
[9] JACS - Folding Simulations
[10] Annual Review of Biochemistry - Secondary Structure Roles
[11] NEJM - Tafamidis Trial
[12] Nature Medicine - CRISPR for Prions
[13] Neuron - α-Synuclein Mutations